Phase I Trial of BAY1251152 for Advanced Blood Cancers

Hematologic Neoplasms Clinical Trial

Official title:

An Open-label, Multicenter Phase I Study to Characterize the Safety, Tolerability, Preliminary Anti-tumor Activity, Pharmacokinetics and Maximum Tolerated Dose of BAY1251152 in Patients With Advanced Hematological Malignancies

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02745743
• Other study ID #: 18117
• Secondary ID: 2015-005122-18
• Status: Completed
• Phase: Phase 1
• Start date: June 17, 2016
• Est. completion date: August 3, 2018

Study information

• Verified date: September 2019
• Source: Bayer
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to identify the most appropriate dose that can be safely administered and that can have an effect on blood cancer cells. Once that safe dose is identified, additional patients will be asked to join the study to further evaluate the safety and effectiveness of the study drug. The study will also investigate the pharmacokinetics (study of what the body does to the drug), as well as pharmacodynamics (study of what the drug does to the body), which may provide information about the effects of BAY 1251152. The study will also measure some biological markers (markers of biological activity in your body) that can be used to predict the response and safety of the proposed treatment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 21
• Est. completion date: August 3, 2018
• Est. primary completion date: August 3, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Male or female patients aged =18 years

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 and Life expectancy of at least 12 weeks

• Patients are able and willing to provide bone marrow biopsies/aspirates as requested by the protocol

• Patients with confirmed advanced hematological malignancies

• Negative serum pregnancy test

• Women and men of reproductive potential must agree to use highly effective contraception when sexually active.

• Ability to understand and the willingness to sign a written informed consent.

• Patients must have adequate coagulation (international normalized ratio (INR) or prothrombin time (PT), partial thromboplastin time (PTT) =1.5 times ULN)

• Adequate liver function (total bilirubin = 1.5 times the ULN, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) = 2.5 times ULN

Exclusion Criteria:

• Presence of active/uncontrolled central nervous system involvement

• History of clinically significant cardiac disease; uncontrolled hypertension

• Left ventricular ejection fraction (LVEF) < 45%

• Allogeneic stem cell transplant within 100 days before first dose of study drug

• Known history of human immunodeficiency virus (HIV) infection

• Chronic or active hepatitis B or C, requiring antiviral therapy

• Evidence of history of bleeding disorder, dialysis, or coexisting cancer that is distinct in primary site or histology from the cancer evaluated in this study

• Serious, uncontrolled infection

• Unresolved chronic toxicity > grade 1 from prior therapy

• Use of strong CYP3A4 inhibitors or strong inducers within 7 days prior to the start of study treatment and for the duration of the study

Related Conditions & MeSH terms

• Hematologic Neoplasms

Intervention

Drug:
• BAY1251152
Weekly infusion of BAY1251152 in 21-day cycles.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Bayer

Countries where clinical trial is conducted

United States,  Germany,  Spain,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum tolerated dose(MTD)	To determine the MTD of BAY1251152 in subjects with advanced hematological neoplasms	21 days
Primary	Recommended Phase 2 dose (RP2D)	To determine the RP2D of BAY1251152 based on safety, tolerability, pharmacokinetic, and pharmacodynamic data in subjects with advanced hematological neoplasms	Up to 30 months
Primary	Number of adverse events (AE)	For assessment of the safety (ECG, vital signs, clinical significant abnormal laboratory results… etc.)and tolerability of BAY 1251152 in subjects with advanced hematological neoplasms	Up to 30 months
Primary	Pharmacokinetics (PK) is determined by maximum concentration (Cmax)		21 days
Primary	Pharmacokinetics (PK) is determined by Area Under concentration versus time Curve (AUC)		21 days
Secondary	Response assessment of BAY 1251152 in hematological malignancies based on the internationally accepted criteria for the specific hematological malignancy which patient is suffering from	To assess the clinical efficacy of BAY 1251152 in subjects with advanced hematological neoplasms	Up to 30 months

External Links

•   Click here to find information about studies related to Bayer Healthcare products conducted in Europe